Tradestie Institutional Equity Comparison Engine

EDIT vs CGON โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGON Overall Edge

CGON Captures Institutional Edge (2โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CG Oncology, Inc. Common stock (CGON) driven by superior Momentum & Technical, Options & Structure while EDIT counters with relative strength in Growth & Margin. Fundamentally, EDIT trades at N/M Forward P/E with -167.0% operating margin (+37.4% YoY revenue) versus CGON at N/M Forward P/E and -4293.5% operating margin (-3.7% YoY). In options structure, EDIT sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro) against CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
EDIT N/M vs CGON N/M Fwd P/E
Growth & Margin Winner EDIT
Op Margin -167.0% vs -4293.5% ยท YoY +37.4% vs -3.7%
Momentum & Technical Winner CGON
1Y -25.0% vs +125.0% ยท 52W Pos 11% vs 84%
Options & Structure Winner CGON
BREAKDOWN (38th %ile IV) vs CONSOLIDATION (85th %ile IV)
EDIT NASDAQ
Editas Medicine, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$1.91
-12.21% 1D
Market Cap $336.5M
1M Return -18.94%
1Y Return -25.0%
Forward P/E N/M
Unified AI Score
51.6 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 69.0 Mom 60.0
CGON NASDAQ
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.17% 1D
Market Cap $6.3B
1M Return +41.93%
1Y Return +124.96%
Forward P/E N/M
Unified AI Score
44.5 / 100 HOLD
Tech 15.0 Fund 43.0 Flow 69.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EDIT -25.0% CGON +124.96% Spread: +149.96 pp (CGON Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period EDIT Revenue CGON Revenue EDIT Op. Margin CGON Op. Margin Margin Edge
FY2018 $30M N/A -356.1% N/A EDIT
FY2019 $20M N/A -686.4% N/A EDIT
FY2020 $90M N/A -148.6% N/A EDIT
FY2021 $30M N/A -756.1% N/A EDIT
FY2022 $20M N/A -1146.3% N/A EDIT
FY2023 $80M $0M -216.6% -27180.9% EDIT
FY2024 $30M $0M -777.2% -10067.3% EDIT
FY2025 $40M $0M -394.9% -4722.1% EDIT

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EDIT (3) vs CGON (5)
Institutional Metric EDIT CGON Criterion Row Winner
Market Capitalization Scale $336.5M $6.3B Larger Scale CGON
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +37.4% -3.7% Higher Growth EDIT
Operating Margin (TTM) Profitability -167.0% -4293.5% Higher Margin EDIT
Net Profit Margin Profitability -144.9% 0.0% Higher Margin CGON
Return on Equity (ROE) Capital Efficiency -147.4% -28.3% Higher ROE CGON
52-Week Range Position Momentum 11% ($2โ€“$4) 84% ($37โ€“$94) Stronger Trend CGON
Beta / 30D Volatility Risk Regime 2.32ฮฒ ยท 102% Vol 0.75ฮฒ ยท 89% Vol Lower Realized Risk CGON
Unified Institutional Score Composite Signal 51.6 / 100 (HOLD) 44.5 / 100 (HOLD) Higher Composite EDIT

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EDIT vs CGON Buy Guide
EDIT BREAKDOWN
146d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 38th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live EDIT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGON CONSOLIDATION
62d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 85th %ile
IV Regime Extreme (>80th %ile)
Live CGON Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EDIT nor CGON registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.